Bempedoic Acid and Cardiovascular Outcomes in Statin . . . The risk of death from cardiovascular causes, nonfatal stroke, or nonfatal myocardial infarction (the first key secondary end point) was 15% lower with bempedoic acid than with placebo, and the
Bempedoic Acid Reduces Major Adverse Cardiovascular Events . . . Tip for Patients: For patients who cannot take a statin, bempedoic acid (Nexletol) is an alternative to statin therapy for prevention of cardiovascular disease in high-risk patients without significant liver or kidney disease
Nexletol shows CLEAR benefit in cardiovascular outcome trial New data for Esperion’s cholesterol lowering daily pill Nexletol, used when statins are not working in people at risk of a heart attack, could inject some momentum into the drug’s slow rollout
Nexletol: Uses, Dosage, Side Effects, Warnings - Drugs. com Nexletol (bempedoic acid) is an oral tablet for high cholesterol that may be used to lower the risk of heart attack and heart procedures (for example stent placement or bypass surgery), in adults not taking a statin who have known heart disease or are at
Esperion Announces New Data from CLEAR Outcomes Highlighting . . . The most common adverse reactions in the cardiovascular outcomes trial for NEXLETOL at an incidence of ≥2% and 0 5% greater than placebo were hyperuricemia, renal impairment, anemia, elevated liver enzymes, muscle spasms, gout, and cholelithiasis
Statin alternative lowers heart-related deaths - Harvard Health The cholesterol-lowering drug bempedoic acid (Nexletol) can be a good alternative for people who can't take statins A 2023 study found that compared with a placebo, bempedoic acid can lower the risk of heart attacks and related problems
NEXLIZET® NEXLETOL® CLEAR Outcomes Trial Information The most common adverse reactions in the cardiovascular outcomes trial for bempedoic acid, a component of NEXLIZET and NEXLETOL, at an incidence of ≥2% and 0 5% greater than placebo were hyperuricemia, renal impairment, anemia, elevated liver enzymes, muscle spasms, gout, and cholelithiasis
In Brief: Cardiovascular Outcomes with Bempedoic Acid (Nexletol) CONCLUSION ― In one large clinical trial in statinintolerant patients who had or were at high-risk for cardiovascular disease, the oral adenosine triphosphate- citrate lyase (ACL) inhibitor bempedoic acid (Nexletol) modestly reduced the risk of a 4-component composite of major adverse cardiovascular events (MACE) compared to placebo
日曆月曆